Results of the clinical and molecular-histological assessment of the effectiveness of the drug PROTEFLAZID® in the treatment of papilomavirus infection in women with cervical intraepithelial neoplasia

Aim — to evaluate the clinical and molecular-morphological effectiveness of the drug PROTEFLAZID® when used in the treatment of human papilloma virus (HPV) infection in women with a cytological koilocytic reaction, as well as in cervical epithelium combined with a mild degree of cervical intraepithelial neoplasia (CIN). Materials and methods. Based on the results of the Pap test and HPV test, 90 women aged 20 to 35 years were involved in the study, who were divided into 3 groups: the group I (control) — 30 women with a negative HPV test and no CIN, the group II — 30 women with a positive HPV test without CIN, the group III — 30 women with CIN I on the background of HPV infection. The article presents the results of a clinical and molecular-histological assessment of the effectiveness of the simultaneous use of oral and vaginal forms of the drug PROTEFLAZID® in the treatment of cervical HPV infection in women, which contributed to the eradication of HPV in 76.7–86.7% of cases, and in combined HPV-infections with cervical intraepithelial neoplasia of a mild degree (CIN I) — in 76.7% of patients until its persistent regression, which was due not only to the antiviral effect of PROTEFLAZID®, but also to its effect, as shown by the results of an immunohistochemical study, on the reduction of the expression of nuclear proteins p16 and Ki-67, which are reverse regulators of the cell cycle and significantly increase when cervical epithelial cells are affected by HPV. Conclusions. The drug PROTEFLAZID® is currently one of the most effective drugs for the treatment of HPV infection, which can be recommended for the eradication of papillomaviruses in women with both low-risk cervical intraepithelial neoplasia (CIN I) and positive HPV-tests with a normal Pap test. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the author.